Investor Presentaiton

5 TRANSACTION OVERVIEW Transaction highlights → US$570m enterprise value 10.8x EV/ LTM EBITDA → ~7x EV/ 2023e EBITDA including synergies Financial impact Financing →EPS and cash accretive from first year → US$15m synergies, fully achieved within 4 years →100% cash → Post acquisition, Arkema's net debt to pro forma EBITDA* around 1.1x → Expected in summer 2019 Closing *Subject to clearance by relevant antitrust authorities * Pro forma EBITDA = consensus for Arkema's 2019e EBITDA + ArrMaz's LTM EBITDA PROPOSED ACQUISITION OF ARRMAZ ARKEMA INNOVATIVE CHEMISTRY

View entire presentation